Englander Institute for Precision Medicine

The NF-κB Transcriptional Footprint Is Essential for SARS-CoV-2 Replication.

TitleThe NF-κB Transcriptional Footprint Is Essential for SARS-CoV-2 Replication.
Publication TypeJournal Article
Year of Publication2021
AuthorsNilsson-Payant BE, Uhl S, Grimont A, Doane AS, Cohen P, Patel RS, Higgins CA, Acklin JA, Bram Y, Chandar V, Blanco-Melo D, Panis M, Lim JK, Elemento O, Schwartz RE, Rosenberg BR, Chandwani R, tenOever BR
JournalJ Virol
Volume95
Issue23
Paginatione0125721
Date Published2021 Nov 09
ISSN1098-5514
KeywordsA549 Cells, Animals, Chlorocebus aethiops, COVID-19, Cytokines, Epigenomics, Gene Expression Regulation, HEK293 Cells, HeLa Cells, Host Microbial Interactions, Humans, Interferon Type I, SARS-CoV-2, Signal Transduction, Single-Cell Analysis, Transcription Factor RelA, Transcription Factors, Transcriptome, Vero Cells, Virus Replication
Abstract

SARS-CoV-2, the etiological agent of COVID-19, is characterized by a delay in type I interferon (IFN-I)-mediated antiviral defenses alongside robust cytokine production. Here, we investigate the underlying molecular basis for this imbalance and implicate virus-mediated activation of NF-κB in the absence of other canonical IFN-I-related transcription factors. Epigenetic and single-cell transcriptomic analyses show a selective NF-κB signature that was most prominent in infected cells. Disruption of NF-κB signaling through the silencing of the NF-κB transcription factor p65 or p50 resulted in loss of virus replication that was rescued upon reconstitution. These findings could be further corroborated with the use of NF-κB inhibitors, which reduced SARS-CoV-2 replication . These data suggest that the robust cytokine production in response to SARS-CoV-2, despite a diminished IFN-I response, is the product of a dependency on NF-κB for viral replication. The COVID-19 pandemic has caused significant mortality and morbidity around the world. Although effective vaccines have been developed, large parts of the world remain unvaccinated while new SARS-CoV-2 variants keep emerging. Furthermore, despite extensive efforts and large-scale drug screenings, no fully effective antiviral treatment options have been discovered yet. Therefore, it is of the utmost importance to gain a better understanding of essential factors driving SARS-CoV-2 replication to be able to develop novel approaches to target SARS-CoV-2 biology.

DOI10.1128/JVI.01257-21
Alternate JournalJ Virol
PubMed ID34523966
PubMed Central IDPMC8577386
Grant ListT32 AI007647 / AI / NIAID NIH HHS / United States
/ / Bill and Melinda Gates Foundation (BMGF) /
S10 OD026880 / OD / NIH HHS / United States
AI151029-01A1 / / Foundation for the National Institutes of Health (FNIH) /
R01 DK121072 / DK / NIDDK NIH HHS / United States
R01 AI151029 / AI / NIAID NIH HHS / United States

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021